Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

that was reportedly also involved in negotiations to buy out the company. If approved, it would become a companion to Merck's Bayer-partnered heart failure drug Verquvo (vericiguat), cleared by ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346. Hengrui Pharma will ...

With the CSF-1R inhibitor space heating up, Merck KGaA ... license to the drug. The German pharma originally paid $70 million for the greater China commercialization rights back in 2023, while ...

including 64 million people in the U.S. Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui ...

a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments. Merck said that the companies are in discussions on the basis ...